Építés alatt – nem éles oldal
Belépés
Résztvevőt keresFázis nélkül

Prediction of Venous Thrombosis During chemotherapy-the PINPOINT Study

A legfontosabb adatok

Ki végzi
University of Dublin, Trinity College
Hol
Írország3 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Résztvevők
380 fő, tervezett
Kezdés
2025. okt. 1.
Várható befejezés
2029. szept. 1.
A vizsgálat típusa
Megfigyeléses
A regiszteradat frissítve
2026. május 15.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with ovarian, lung, gastric or pancreatic cancer who are about to start chemotherapy. Blood tests will check clotting markers to predict blood clots.

Életkor
Over 18 years
Nem
All
A betegség stádiuma
Ovarian, lung, gastric or pancreatic cancer. Chemotherapy before or after surgery, chemotherapy for cancer that came back, or targeted therapy given with chemotherapy.
Korábbi kezelés
People must be scheduled to start a course of chemotherapy. They cannot have had chemotherapy or immunotherapy 4 weeks before the first blood sample.

A részvétel fő kizáró okai

  • A blood clot in a vein in the last 5 years (some clots linked to a central line are allowed)
  • Serious bleeding needing hospital care or transfusion, outside surgery, in the last 5 years
  • An inherited bleeding disorder, or known disseminated intravascular coagulation (a severe clotting disorder)
  • Surgery within 2 weeks of the first blood sample, except port-a-cath placement or biopsy
  • Currently taking long-term blood thinners such as LMWH, DOACs or Warfarin

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients with a diagnosis of ovarian, lung, gastric or pancreatic cancer scheduled to undergo a course of chemotherapy who are undergoing adjuvant or neoadjuvant chemotherapy, or who are undergoing chemotherapy for relapsed disease or patients receiving targeted therapy in combination with chemotherapy
  • Patients who are over 18 years of age
  • Patients who are able to give full and informed written consent

Ki nem vehet részt

  • Prior history of a documented VTE event within the last 5 years (excluding central line associated events whereby patients completed anticoagulation > 3 months previously)
  • Surgery within 2 weeks of first baseline sample (with the exception of porth-a-cath implantation or biopsy)
  • Chemotherapy or immunotherapy 4 weeks before first baseline sample
  • Currently receiving long term anticoagulant therapy (Low Molecular Weight Heparin(LMWH), Direct Oral Anticoagulants(DOACs), Warfarin). Patients receiving aspirin, ticlopidine, clopidogrel or LMWH at a prophylactic dosage for a short period (ie post cancer surgery or during short hospital stay) will be included provided they have completed thromboprophylaxis therapy at the first blood sampling time point
  • Any history of significant haemorrhage (requiring hospitalization or transfusion) outside of a surgical setting within the last 5 years
  • Familial bleeding diathesis
  • Known diagnosis of disseminated intravascular coagulation

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Cancer patients are at higher risk of getting a blood clot (known as venous thromboembolism (VTE)) especially during chemotherapy and some patients are more at risk than others. These clots can be prevented by using blood thinners (known as anticoagulants) but these are not suitable for everyone as they also carry a risk of bleeding. This study aims to identify which chemotherapy patients are most at risk of a blood clot and at what point in their treatment this is likely to happen. In this project biomarkers in the blood that are involved in blood clotting will be measured in cancer patients at four stages during chemotherapy to see how the biomarkers change during treatment. The blood samples for these tests are taken at the same time as the normal routine blood tests done before a chemotherapy cycle. Biomarker levels will be compared between those patients who subsequently get a VTE and those who do not get a VTE. This will help develop a biomarker based blood test to predict clots during chemotherapy. The biomarker based test will also be compared with other methods of predicting VTE in cancer patients which are currently in use. In the future, this blood test might be used to see if patients are at high risk of a clot during chemotherapy and provide a method to optimise the use of preventative anticoagulants in cancer patients during chemotherapy.

A vizsgálat csoportja

  • Cancer patients undergoing chemotherapy

    Lung, ovarian and pancreatic cancer patients undergoing chemotherapy.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Prediction and Prevention of Venous Thrombo-embolism(VTE) During Chemotherapy Using Serial Determination of Haemostasis Biomarkers.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. május 15.